Literature DB >> 21307201

The leader proteinase of foot-and-mouth disease virus negatively regulates the type I interferon pathway by acting as a viral deubiquitinase.

Dang Wang1, Liurong Fang, Ping Li, Li Sun, Jinxiu Fan, Qingye Zhang, Rui Luo, Xiangtao Liu, Kui Li, Huanchun Chen, Zhongbin Chen, Shaobo Xiao.   

Abstract

The leader proteinase (L(pro)) of foot-and-mouth disease virus (FMDV) is a papain-like proteinase that plays an important role in FMDV pathogenesis. Previously, it has been shown that L(pro) is involved in the inhibition of the type I interferon (IFN) response by FMDV. However, the underlying mechanisms remain unclear. Here we demonstrate that FMDV Lb(pro), a shorter form of L(pro), has deubiquitinating activity. Sequence alignment and structural bioinformatics analyses revealed that the catalytic residues (Cys51 and His148) are highly conserved in FMDV Lb(pro) of all seven serotypes and that the topology of FMDV Lb(pro) is remarkably similar to that of ubiquitin-specific protease 14 (USP14), a cellular deubiquitylation enzyme (DUB), and to that of severe acute respiratory syndrome coronavirus (SARS-CoV) papain-like protease (PLpro), a coronaviral DUB. Both purified Lb(pro) protein and in vivo ectopically expressed Lb(pro) removed ubiquitin (Ub) moieties from cellular substrates, acting on both lysine-48- and lysine-63-linked polyubiquitin chains. Furthermore, Lb(pro) significantly inhibited ubiquitination of retinoic acid-inducible gene I (RIG-I), TANK-binding kinase 1 (TBK1), TNF receptor-associated factor 6 (TRAF6), and TRAF3, key signaling molecules in activation of type I IFN response. Mutations in Lb(pro) that ablate the catalytic activity (C51A or D163N/D164N) or disrupt the SAP (for SAF-A/B, Acinus, and PIAS) domain (I83A/L86A) abrogated the DUB activity of Lb(pro) as well as its ability to block signaling to the IFN-β promoter. Collectively, these results demonstrate that FMDV Lb(pro) possesses DUB activity in addition to serving as a viral proteinase and describe a novel mechanism evolved by FMDV to counteract host innate antiviral responses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21307201      PMCID: PMC3126127          DOI: 10.1128/JVI.02589-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

Review 1.  Molecular basis of pathogenesis of FMDV.

Authors:  Peter W Mason; Marvin J Grubman; Barry Baxt
Journal:  Virus Res       Date:  2003-01       Impact factor: 3.303

2.  Recognition of eukaryotic initiation factor 4G isoforms by picornaviral proteinases.

Authors:  Nicole Foeger; Walter Glaser; Tim Skern
Journal:  J Biol Chem       Date:  2002-09-11       Impact factor: 5.157

Review 3.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

4.  The two species of the foot-and-mouth disease virus leader protein, expressed individually, exhibit the same activities.

Authors:  M Medina; E Domingo; J K Brangwyn; G J Belsham
Journal:  Virology       Date:  1993-05       Impact factor: 3.616

5.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling.

Authors:  Ingrid E Wertz; Karen M O'Rourke; Honglin Zhou; Michael Eby; L Aravind; Somasekar Seshagiri; Ping Wu; Christian Wiesmann; Rohan Baker; David L Boone; Averil Ma; Eugene V Koonin; Vishva M Dixit
Journal:  Nature       Date:  2004-07-18       Impact factor: 49.962

6.  Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity.

Authors:  Paul C Evans; Huib Ovaa; Maureen Hamon; Peter J Kilshaw; Svetlana Hamm; Stefan Bauer; Hidde L Ploegh; Trevor S Smith
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

7.  Two initiation sites for foot-and-mouth disease virus polyprotein in vivo.

Authors:  B E Clarke; D V Sangar; J N Burroughs; S E Newton; A R Carroll; D J Rowlands
Journal:  J Gen Virol       Date:  1985-12       Impact factor: 3.891

8.  The foot-and-mouth disease virus leader proteinase gene is not required for viral replication.

Authors:  M E Piccone; E Rieder; P W Mason; M J Grubman
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  Identification of critical amino acids within the foot-and-mouth disease virus leader protein, a cysteine protease.

Authors:  P J Roberts; G J Belsham
Journal:  Virology       Date:  1995-10-20       Impact factor: 3.616

10.  Putative papain-related thiol proteases of positive-strand RNA viruses. Identification of rubi- and aphthovirus proteases and delineation of a novel conserved domain associated with proteases of rubi-, alpha- and coronaviruses.

Authors:  A E Gorbalenya; E V Koonin; M M Lai
Journal:  FEBS Lett       Date:  1991-08-19       Impact factor: 4.124

View more
  108 in total

1.  Arterivirus and nairovirus ovarian tumor domain-containing Deubiquitinases target activated RIG-I to control innate immune signaling.

Authors:  Puck B van Kasteren; Corrine Beugeling; Dennis K Ninaber; Natalia Frias-Staheli; Sander van Boheemen; Adolfo García-Sastre; Eric J Snijder; Marjolein Kikkert
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Inhibition of RIG-I-mediated signaling by Kaposi's sarcoma-associated herpesvirus-encoded deubiquitinase ORF64.

Authors:  Kyung-Soo Inn; Sun-Hwa Lee; Jessica Y Rathbun; Lai-Yee Wong; Zsolt Toth; Keigo Machida; Jing-Hsiung James Ou; Jae U Jung
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Foot-and-Mouth Disease Virus Leader Protease Cleaves G3BP1 and G3BP2 and Inhibits Stress Granule Formation.

Authors:  Linda J Visser; Gisselle N Medina; Huib H Rabouw; Raoul J de Groot; Martijn A Langereis; Teresa de Los Santos; Frank J M van Kuppeveld
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

4.  Robust Protection against Highly Virulent Foot-and-Mouth Disease Virus in Swine by Combination Treatment with Recombinant Adenoviruses Expressing Porcine Alpha and Gamma Interferons and Multiple Small Interfering RNAs.

Authors:  Su-Mi Kim; Jong-Hyeon Park; Kwang-Nyeong Lee; Se-Kyung Kim; Su-Hwa You; Taeseong Kim; Dongseob Tark; Hyang-Sim Lee; Min-Goo Seo; Byounghan Kim
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

Review 5.  Toll-like receptors: key players in antiviral immunity.

Authors:  Nicholas Arpaia; Gregory M Barton
Journal:  Curr Opin Virol       Date:  2011-10-28       Impact factor: 7.090

6.  Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF-κB signaling during productive replication.

Authors:  Shinichi Saito; Takayuki Murata; Teru Kanda; Hiroki Isomura; Yohei Narita; Atsuko Sugimoto; Daisuke Kawashima; Tatsuya Tsurumi
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

7.  Deubiquitinase function of arterivirus papain-like protease 2 suppresses the innate immune response in infected host cells.

Authors:  Puck B van Kasteren; Ben A Bailey-Elkin; Terrence W James; Dennis K Ninaber; Corrine Beugeling; Mazdak Khajehpour; Eric J Snijder; Brian L Mark; Marjolein Kikkert
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

8.  Porcine Epidemic Diarrhea Virus 3C-Like Protease Regulates Its Interferon Antagonism by Cleaving NEMO.

Authors:  Dang Wang; Liurong Fang; Yanling Shi; Huan Zhang; Li Gao; Guiqing Peng; Huanchun Chen; Kui Li; Shaobo Xiao
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

Review 9.  Deubiquitinating enzymes as promising drug targets for infectious diseases.

Authors:  Bindu Nanduri; Akamol E Suvarnapunya; Malabi Venkatesan; Mariola J Edelmann
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Foot-and-Mouth Disease Virus 3B Protein Interacts with Pattern Recognition Receptor RIG-I to Block RIG-I-Mediated Immune Signaling and Inhibit Host Antiviral Response.

Authors:  Xiangle Zhang; Zixiang Zhu; Congcong Wang; Fan Yang; Weijun Cao; Pengfei Li; Xiaoli Du; Furong Zhao; Xiangtao Liu; Haixue Zheng
Journal:  J Immunol       Date:  2020-09-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.